EA201600316A2 - ANTITUBERCULOSIC VACCINE ON THE BASIS OF RECOMBINANT PROTEINS Ag85B, TB10.4, FLiC - Google Patents
ANTITUBERCULOSIC VACCINE ON THE BASIS OF RECOMBINANT PROTEINS Ag85B, TB10.4, FLiCInfo
- Publication number
- EA201600316A2 EA201600316A2 EA201600316A EA201600316A EA201600316A2 EA 201600316 A2 EA201600316 A2 EA 201600316A2 EA 201600316 A EA201600316 A EA 201600316A EA 201600316 A EA201600316 A EA 201600316A EA 201600316 A2 EA201600316 A2 EA 201600316A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- safe
- excipient
- create
- vaccine
- erudite
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Изобретение относится к молекулярной биологии, биотехнологии, медицине. Предложена противотуберкулезная вакцина, содержащая рекомбинантные белки Ag85B и ТВ10.4 M.tuherculosis, а также рекомбинантный адъювант - флагеллин FliC Salmonella enterica serovar Typhimurium, а также фармацевтически приемлемый эксципиент, для решения острой задачи современности, заключающейся в создании безопасной при производстве и применении противотуберкулезной вакцины, имеющей эффективность, как минимум, сравнимую с таковой БЦЖ. Указанные свойства предложенной вакцины подтверждены примерами.The invention relates to molecular biology, biotechnology, medicine. An anti-tuberculosis vaccine containing recombinant proteins Ag85B and TB10.4 M.tuherculosis, as well as recombinant adjuvant - flagellin FliC Salmonella enterica serovar Typhimurium, as well as a pharmaceutically acceptable excipient, are proposed for solving the acute problem of modernity, which is to create a safe environment, to create a safe, erudite excipient for solving a modern problem, which is to create a safe, erudite excipient, to create a safe, modern, effective excipient to solve an acute problem of modernity that creates a safe, erudite excipient, which creates a safe, erudable excipient, which creates a safe, discharging antigen. with efficacy at least comparable to that of BCG. These properties of the proposed vaccine are confirmed by examples.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015109715/15A RU2015109715A (en) | 2015-03-19 | 2015-03-19 | ANTITUBERCULOSIS VACCINE BASED ON RECOMBINANT PROTEINS Ag85B, TB10.4, FliC |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201600316A2 true EA201600316A2 (en) | 2016-10-31 |
EA201600316A3 EA201600316A3 (en) | 2016-11-30 |
EA031495B1 EA031495B1 (en) | 2019-01-31 |
Family
ID=53880100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201600316A EA031495B1 (en) | 2015-03-19 | 2016-05-05 | ANTITUBERCULOSIS VACCINE BASED ON RECOMBINANT Ag85B, TB10.4, FliC PROTEINS |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA031495B1 (en) |
RU (1) | RU2015109715A (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101684447B1 (en) * | 2008-06-25 | 2016-12-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | Novel immunoadjuvant flagellin-based compounds and use thereof |
US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
RU2524133C2 (en) * | 2012-11-15 | 2014-07-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Escherichia coli BACTERIA STRAIN - PRODUCER OF RECOMBINANT FLAGELLIN |
-
2015
- 2015-03-19 RU RU2015109715/15A patent/RU2015109715A/en not_active Application Discontinuation
-
2016
- 2016-05-05 EA EA201600316A patent/EA031495B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA201600316A3 (en) | 2016-11-30 |
EA031495B1 (en) | 2019-01-31 |
RU2015109715A (en) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124288T1 (en) | CMV VACCINE | |
BR112016028816A8 (en) | immunogenic combination, method of obtaining a specific immune response, use of an immunogenic combination, and, vaccination regimen for the prevention, reduction or treatment of respiratory syncytial virus infection | |
MX2023013140A (en) | Vaccines against hepatitis b virus. | |
EA201890735A1 (en) | Modulators of the cow protein of the hepatitis B virus | |
CY1119435T1 (en) | PACKAGE FOR ANTI-ALPHA4VITA7 | |
BR112018068748A2 (en) | compound, pharmaceutical and vaccine composition, methods for inducing or promoting an immune response, for treating cancer, infectious diseases, immunological disorders and immunological diseases, and for treating or preventing a disease, and, using a compound | |
EA201791702A1 (en) | THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS | |
BR112016028288A2 (en) | compound, pharmaceutical composition, methods for treating an individual with a disease or condition and for inhibiting kinase, and use of a compound. | |
BR112017008165A2 (en) | single domain antibodies directed against intracellular antigens | |
BR112016028066A2 (en) | vaccine composition; idessuis; ridessuis; antibody; parenteral composition; use of an idessuis or ridessuis protein; and host cell | |
EA201591579A1 (en) | METHODS OF TREATMENT OF CROWN DISEASE WITH ANTI-IL-23 ANTIBODIES | |
WO2015143123A3 (en) | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof | |
EA201790239A1 (en) | MOLECULE CARRIER FOR ANTIGENS | |
CL2018000565A1 (en) | Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others. | |
CY1121554T1 (en) | PRODUCER OF PYRANOCHROMENYL-PHENOLIS, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME OR INFLAMMATORY DISEASE | |
BR112015030229A8 (en) | VIRUS-LIKE PARTICLE COMPRISING A POLYPEPTIDE AND A MALARIA ANTIGEN, VECTOR, PHARMACEUTICAL AND VACCINE COMPOSITIONS, AS WELL AS ISOLATED NUCLEIC ACID MOLECULE | |
BR112017012381A2 (en) | immunotherapy for angiogenic disease | |
BR112015025748A2 (en) | DNA construction for immunomodulation, pharmaceutical composition, vaccine, and use of a DNA construction | |
BR112016012599A2 (en) | composition and method for treating or preventing a staphylococcus aureus infection | |
PH12016501988A1 (en) | Antibacterial compounds | |
BR112017004796A2 (en) | method for using hydroxamic acid derivatives and antibacterial substance in combination | |
EA201692111A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES | |
EA201990451A1 (en) | COMPOSITION OF MULTI-VALENT PNEUMO-COCK CAPSULE POLYSACCHARIDE COMPOUNDS WITH PROTEIN-CARRIER AND ITS APPLICATION | |
UY36217A (en) | PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE. | |
BR112017024126B8 (en) | PHARMACEUTICAL COMPOSITIONS, MICRONIZED COMPOUND A AND/OR AT LEAST ONE MICRONIZED PHARMACEUTICALLY ACCEPTABLE SALT OF COMPOUND A AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KZ |